EB #2: New Basal Insulins Reduce the Incidence of Hypoglycemia

Hypoglycemia, although often unrecognized or discussed, is the most frequent side effect of insulin and can increased risk of adverse outcomes, cardiovascular events, and death, and has a significant impact on patients’ quality of life. In this expert brief, pharmacists Carol Wei and Tom Smiley will discuss technologies that can help patients and clinicians identify and track glycemic variability and reduce hypoglycemic events. This expert brief will also address the newer, long-lasting insulins that have been shown to result in more stable control of fasting glucose levels with lower risk of hypoglycemia, especially nocturnal hypoglycemia.